Clinical Trials


Select item(s)
Key Findings
A phase2/3 trial of the ChAdOx1 nCoV-19 vaccine shows that it is safe and well-tolerated in older and young adults. Local reactions were more common than systemic reactions. Fewer adverse reactions were reported after the booster dose and reduced with increasing age.
PMID 33220855
Title Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
Author(s) nameRamasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, Voysey M, Aley PK, Angus B, Babbage G, Belij-Rammerstorfer S, Berry L, Bibi S, Bittaye M, Cathie K, Chappell H, Charlton S, Cicconi P, Clutterbuck EA, Colin-Jones R, Dold C, Emary KRW, Fedosyuk S, Fuskova M, Gbesemete D, Green C, Hallis B, Hou MM, Jenkin D, Joe CCD, Kelly EJ, Kerridge S, Lawrie AM, Lelliott A, Lwin MN, Makinson R, Marchevsky NG, Mujadidi Y, Munro APS, Pacurar M, Plested E, Rand J, Rawlinson T, Rhead S, Robinson H, Ritchie AJ, Ross-Russell AL, Saich S, Singh N, Smith CC, Snape MD, Song R, Tarrant R, Themistocleous Y, Thomas KM, Villafana TL, Warren SC, Watson MEE, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Faust SN, Pollard AJ; Oxford COVID Vaccine Trial Group.
Journal Lancet
Impact factor43.38
Citation count26
Date of publishing2021 Dec 19
In a phase2/3 trial of the ChAdOx1 nCoV-19 vaccine, immunogenecity was found to be similar across all age groups after the booster dose.
PMID 33220855
Title Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
Author(s) nameRamasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, Voysey M, Aley PK, Angus B, Babbage G, Belij-Rammerstorfer S, Berry L, Bibi S, Bittaye M, Cathie K, Chappell H, Charlton S, Cicconi P, Clutterbuck EA, Colin-Jones R, Dold C, Emary KRW, Fedosyuk S, Fuskova M, Gbesemete D, Green C, Hallis B, Hou MM, Jenkin D, Joe CCD, Kelly EJ, Kerridge S, Lawrie AM, Lelliott A, Lwin MN, Makinson R, Marchevsky NG, Mujadidi Y, Munro APS, Pacurar M, Plested E, Rand J, Rawlinson T, Rhead S, Robinson H, Ritchie AJ, Ross-Russell AL, Saich S, Singh N, Smith CC, Snape MD, Song R, Tarrant R, Themistocleous Y, Thomas KM, Villafana TL, Warren SC, Watson MEE, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Faust SN, Pollard AJ; Oxford COVID Vaccine Trial Group.
Journal Lancet
Impact factor43.38
Citation count26
Date of publishing2021 Dec 19
Among the 175 adverse events reported during the clinical trial with the Pfizer-BioNTech COVID-19 vaccine, severe allergic reactions including anaphylaxis were reviewed.
PMID 33444297
Title Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine United States, December 1423, 2020
Author(s) nameCDC COVID-19 Response Team; Food and Drug Administration.
Journal MMWR Morb Mortal Wkly Rep
Impact factor14.4
Citation count9
Date of publishing2021 Jan 15
In a phase1/2 clinical trial, BBIBP-CorV inactivated vaccine given in a 2 dose regimen was found to be safe and well-tolerated.
PMID 33069281
Title Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial
Author(s) nameXia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, Tan W, Wu G, Xu M, Lou Z, Huang W, Xu W, Huang B, Wang H, Wang W, Zhang W, Li N, Xie Z, Ding L, You W, Zhao Y, Yang X, Liu Y, Wang Q, Huang L, Yang Y, Xu G, Luo B, Wang W, Liu P, Guo W, Yang X.
Journal Lancet Infect Dis
Impact factor21.77
Citation count17
Date of publishing2021 Jan
In a phase1/2 clinical trial, BBIBP-CorV inactivated vaccine given in a 2 dose regimen was found to be safe and well-tolerated. The vaccine-induced a robust humoral response in 100% of the vaccine recipients.
PMID 33069281
Title Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial
Author(s) nameXia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, Tan W, Wu G, Xu M, Lou Z, Huang W, Xu W, Huang B, Wang H, Wang W, Zhang W, Li N, Xie Z, Ding L, You W, Zhao Y, Yang X, Liu Y, Wang Q, Huang L, Yang Y, Xu G, Luo B, Wang W, Liu P, Guo W, Yang X.
Journal Lancet Infect Dis
Impact factor21.77
Citation count17
Date of publishing2021 Jan
In a phase1/2 clinical trail, BBIBP-CorV inactivated vaccine given in a 2 dose regimen was found to be safe and well tolerated. The vaccine induced a robust humoral response 1n 100% of the vaccine recipients.
PMID 33069281
Title Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial
Author(s) nameXia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, Tan W, Wu G, Xu M, Lou Z, Huang W, Xu W, Huang B, Wang H, Wang W, Zhang W, Li N, Xie Z, Ding L, You W, Zhao Y, Yang X, Liu Y, Wang Q, Huang L, Yang Y, Xu G, Luo B, Wang W, Liu P, Guo W, Yang X.
Journal Lancet Infect Dis
Impact factor21.77
Citation count17
Date of publishing2021 Jan
In a phase1/2 clinical trial, BBIBP-CorV inactivated vaccine given in a 2 dose regimen was found to be safe and well-tolerated. The vaccine-induced a robust humoral response in 100% of the vaccine recipients.
PMID 33069281
Title Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial
Author(s) nameXia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, Tan W, Wu G, Xu M, Lou Z, Huang W, Xu W, Huang B, Wang H, Wang W, Zhang W, Li N, Xie Z, Ding L, You W, Zhao Y, Yang X, Liu Y, Wang Q, Huang L, Yang Y, Xu G, Luo B, Wang W, Liu P, Guo W, Yang X.
Journal Lancet Infect Dis
Impact factor21.77
Citation count17
Date of publishing2021 Jan
In four ongoing blinded, randomized, controlled trials done across the UK, Brazil, and South Africa, the ChAdOx1 nCoV-19 vaccine was found to be safe and efficacious against COVID-19
PMID 33306989
Title Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
Author(s) nameVoysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, Bibi S, Briner C, Cicconi P, Collins AM, Colin-Jones R, Cutland CL, Darton TC, Dheda K, Duncan CJA, Emary KRW, Ewer KJ, Fairlie L, Faust SN, Feng S, Ferreira DM, Finn A, Goodman AL, Green CM, Green CA, Heath PT, Hill C, Hill H, Hirsch I, Hodgson SHC, Izu A, Jackson S, Jenkin D, Joe CCD, Kerridge S, Koen A, Kwatra G, Lazarus R, Lawrie AM, Lelliott A, Libri V, Lillie PJ, Mallory R, Mendes AVA, Milan EP, Minassian AM, McGregor A, Morrison H, Mujadidi YF, Nana A, O'Reilly PJ, Padayachee SD, Pittella A, Plested E, Pollock KM, Ramasamy MN, Rhead S, Schwarzbold AV, Singh N, Smith A, Song R, Snape MD, Sprinz E, Sutherland RK, Tarrant R, Thomson EC, Török ME, Toshner M, Turner DPJ, Vekemans J, Villafana TL, Watson MEE, Williams CJ, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Pollard AJ; Oxford COVID Vaccine Trial Group.
Journal Lancet
Impact factor43.38
Citation count28
Date of publishing2020 Dec 8
In a placebo-controlled, observer-blinded, pivotal efficacy trial, nucleoside-modified RNA vaccine BNT162b2 was found to be safe with very low incidences of serious adverse events. The adverse events reported were mild or moderate and reactions were more common in younger adults compared to older adults.
PMID 33301246
Title Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Author(s) namePolack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV, Cooper D, Frenck RW Jr, Hammitt LL, Türeci Ö, Nell H, Schaefer A, Ünal S, Tresnan DB, Mather S, Dormitzer PR, Şahin U, Jansen KU, Gruber WC; C4591001 Clinical Trial Group.
Journal N Engl J Med
Impact factor37.91
Citation count67
Date of publishing2020 Dec 31
In a placebo-controlled, observer-blinded, pivotal efficacy trial, nucleoside-modified RNA vaccine BNT162b2 was found to be 95% effective in preventing COVID-19 infection.
PMID 33301246
Title Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Author(s) namePolack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV, Cooper D, Frenck RW Jr, Hammitt LL, Türeci Ö, Nell H, Schaefer A, Ünal S, Tresnan DB, Mather S, Dormitzer PR, Şahin U, Jansen KU, Gruber WC; C4591001 Clinical Trial Group.
Journal N Engl J Med
Impact factor37.91
Citation count67
Date of publishing2020 Dec 31
In phase 3 clinical trial study, the mRNA-1273 vaccine was found to be safe. The local reactions to the vaccine were mild to moderate and resolved within a day or two.
PMID 33378609
Title Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Author(s) nameBaden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, McGettigan J, Khetan S, Segall N, Solis J, Brosz A, Fierro C, Schwartz H, Neuzil K, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Mascola J, Polakowski L, Ledgerwood J, Graham BS, Bennett H, Pajon R, Knightly C, Leav B, Deng W, Zhou H, Han S, Ivarsson M, Miller J, Zaks T; COVE Study Group.
Journal N Engl J Med
Impact factor37.91
Citation count16
Date of publishing2020 Dec 30
The INO-4800 DNA vaccine was immunogenic in 100% (38/38) of the vaccinated subjects. The vaccine elicited both cellular and humoral immune responses in all subjects.
PMID 33392485
Title Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial
Author(s) nameTebas P, Yang S, Boyer JD, Reuschel EL, Patel A, Christensen-Quick A, Andrade VM, Morrow MP, Kraynyak K, Agnes J, Purwar M, Sylvester A, Pawlicki J, Gillespie E, Maricic I, Zaidi FI, Kim KY, Dia Y, Frase D, Pezzoli P, Schultheis K, Smith TRF, Ramos SJ, McMullan T, Buttigieg K, Carroll MW, Ervin J, Diehl MC, Blackwood E, Mammen MP, Lee J, Dallas MJ, Brown AS, Shea JE, Kim JJ, Weiner DB, Broderick KE, Humeau LM.
Journal EClinicalMedicine
Impact factor6.68
Citation count2
Date of publishing2020 Dec 24
The INO-4800 DNA vaccine was found to be safe. Out of the 11 adverse events reported, only 6 were related to the INO-4800 vaccine.
PMID 33392485
Title Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial
Author(s) nameTebas P, Yang S, Boyer JD, Reuschel EL, Patel A, Christensen-Quick A, Andrade VM, Morrow MP, Kraynyak K, Agnes J, Purwar M, Sylvester A, Pawlicki J, Gillespie E, Maricic I, Zaidi FI, Kim KY, Dia Y, Frase D, Pezzoli P, Schultheis K, Smith TRF, Ramos SJ, McMullan T, Buttigieg K, Carroll MW, Ervin J, Diehl MC, Blackwood E, Mammen MP, Lee J, Dallas MJ, Brown AS, Shea JE, Kim JJ, Weiner DB, Broderick KE, Humeau LM.
Journal EClinicalMedicine
Impact factor6.68
Citation count2
Date of publishing2020 Dec 24
In a phase 1/2 trial, NVX-CoV2373, a recombinant severe acute respiratory syndrome coronavirus 2 (rSARS-CoV-2) nanoparticle vaccine was found to be safe and elicited an immune response that exceeded levels in COVID-19 convalescent serum.
PMID 32877576
Title Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine
Author(s) nameKeech C, Albert G, Cho I, Robertson A, Reed P, Neal S, Plested JS, Zhu M, Cloney-Clark S, Zhou H, Smith G, Patel N, Frieman MB, Haupt RE, Logue J, McGrath M, Weston S, Piedra PA, Desai C, Callahan K, Lewis M, Price-Abbott P, Formica N, Shinde V, Fries L, Lickliter JD, Griffin P, Wilkinson B, Glenn GM.
Journal N Engl J Med
Impact factor37.91
Citation count72
Date of publishing2020 Dec 10
In a phase 1/2 trial, NVX-CoV2373, a recombinant severe acute respiratory syndrome coronavirus 2 (rSARS-CoV-2) nanoparticle vaccine was found to be safe and elicited an immune response that exceeded levels in COVID-19 convalescent serum.
PMID 32877576
Title Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine
Author(s) nameKeech C, Albert G, Cho I, Robertson A, Reed P, Neal S, Plested JS, Zhu M, Cloney-Clark S, Zhou H, Smith G, Patel N, Frieman MB, Haupt RE, Logue J, McGrath M, Weston S, Piedra PA, Desai C, Callahan K, Lewis M, Price-Abbott P, Formica N, Shinde V, Fries L, Lickliter JD, Griffin P, Wilkinson B, Glenn GM.
Journal N Engl J Med
Impact factor37.91
Citation count72
Date of publishing2020 Dec 10
In a phase I/II study of COVID-19 RNA vaccine BNT162b1, local and systemic events were mild to moderate and transient.
PMID 32785213
Title PhaseI/II study of COVID-19 RNA vaccine BNT162b1 in adults
Author(s) nameMulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Raabe V, Bailey R, Swanson KA, Li P, Koury K, Kalina W, Cooper D, Fontes-Garfias C, Shi PY, Türeci Ö, Tompkins KR, Walsh EE, Frenck R, Falsey AR, Dormitzer PR, Gruber WC, Şahin U, Jansen KU.
Journal Nature
Impact factor24.36
Citation count49
Date of publishing2020 Oct
In a phase I/II study of COVID-19 RNA vaccine BNT162b1 showed good immunogenicity and showed a good amount of RBD-binding IgG titers.
PMID 32785213
Title PhaseI/II study of COVID-19 RNA vaccine BNT162b1 in adults
Author(s) nameMulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Raabe V, Bailey R, Swanson KA, Li P, Koury K, Kalina W, Cooper D, Fontes-Garfias C, Shi PY, Türeci Ö, Tompkins KR, Walsh EE, Frenck R, Falsey AR, Dormitzer PR, Gruber WC, Şahin U, Jansen KU.
Journal Nature
Impact factor24.36
Citation count49
Date of publishing2020 Oct